Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of Arizona Univ Arizona
mi
from
*see Various Departments*, AZ
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of Arizona Univ Arizona
mi
from
*see Various Departments*, AZ
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of Arkansas/ Arkansas Cancer Research Center UAMS
mi
from
Little Rock, AR
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of Arkansas/ Arkansas Cancer Research Center UAMS
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of California Irvine University of California Irvin
mi
from
Orange, CA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of California Irvine University of California Irvin
mi
from
Orange, CA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
cCare Encinitas Location
mi
from
San Diego, CA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
cCare Encinitas Location
mi
from
San Diego, CA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of California San Deigo - Moores Cancer Dept. of Moores Cancer Center
mi
from
San Diego, CA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of California San Deigo - Moores Cancer Dept. of Moores Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Emory University School of Medicine/Winship Cancer Institute Emory 3
mi
from
Atlanta, GA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Emory University School of Medicine/Winship Cancer Institute Emory 3
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Georgia Health Sciences University Georgia Health 2
mi
from
Augusta, GA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Georgia Health Sciences University Georgia Health 2
mi
from
Augusta, GA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University Chicago Hospital Dept. of Univ of Chicago (2)
mi
from
Chicago, IL
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University Chicago Hospital Dept. of Univ of Chicago (2)
mi
from
Chicago, IL
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Indiana University Indiana Univ 2
mi
from
Indianapolis, IN
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Indiana University Indiana Univ 2
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Stormont Vail Healthcare - Cotton-O'Neil Clinic Stormont-Vail
mi
from
Topeka, KA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Stormont Vail Healthcare - Cotton-O'Neil Clinic Stormont-Vail
mi
from
Topeka, KA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Hematology and Oncology Specialists Dept of Hem&Onc Specialist - 2
mi
from
Metairie, LA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Hematology and Oncology Specialists Dept of Hem&Onc Specialist - 2
mi
from
Metairie, LA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Dana Farber Cancer Institute DFCI LG100
mi
from
Boston, MA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Dana Farber Cancer Institute DFCI LG100
mi
from
Boston, MA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University Missouri Ellis Fischel Cancer Center Univ Missouri
mi
from
Columbia, MO
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University Missouri Ellis Fischel Cancer Center Univ Missouri
mi
from
Columbia, MO
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Memorial Sloan Kettering Cancer Center MSKCC
mi
from
New York, NY
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Memorial Sloan Kettering Cancer Center MSKCC
mi
from
New York, NY
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Weill Cornell Medical College Cornell 2
mi
from
New York, NY
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Weill Cornell Medical College Cornell 2
mi
from
New York, NY
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Duke University Medical Center Duke 2
mi
from
Durham, NC
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Duke University Medical Center Duke 2
mi
from
Durham, NC
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Akron City Hospital Summa Health System Akron
mi
from
Akron, OH
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Akron City Hospital Summa Health System Akron
mi
from
Akron, OH
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital
mi
from
Columbus, OH
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Oregon Health & Science University StudyCoordinator:CBHQ880A2203
mi
from
Portland, OR
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Oregon Health & Science University StudyCoordinator:CBHQ880A2203
mi
from
Portland, OR
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
The Baylor College of Medicine/The Methodist Hospital Methodist
mi
from
Houston, TX
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
The Baylor College of Medicine/The Methodist Hospital Methodist
mi
from
Houston, TX
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
MD Anderson Cancer Center/University of Texas Univ TX MD Anderson
mi
from
Houston, TX
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
MD Anderson Cancer Center/University of Texas Univ TX MD Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3)
mi
from
San Antonio, TX
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Medical Oncology Associates PS
mi
from
Spokane, WA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Medical Oncology Associates PS
mi
from
Spokane, WA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Dean Health System Hem Onc
mi
from
Madison, WI
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Dean Health System Hem Onc
mi
from
Madison, WI
Click here to add this to my saved trials
Urinary Biomarkers of the Progression of Alport Kidney Disease
Urinary Biomarkers of the Progression of Alport Kidney Disease
Status: Enrolling
Updated:  10/10/2012
Univ of Minnesota
mi
from
Minneapolis, MN
Urinary Biomarkers of the Progression of Alport Kidney Disease
Urinary Biomarkers of the Progression of Alport Kidney Disease
Status: Enrolling
Updated: 10/10/2012
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Birmingham, AL
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Aurora, CO
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Decatur, GA
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Overland Park, KA
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Metairie, LA
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Baltimore, MD
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Jackson, MS
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Omaha, NE
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Henderson, NV
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Ashville, NC
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Cleveland, OH
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Charleston, SC
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Research Across America
mi
from
Northeast, TX
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Research Across America
mi
from
Northeast, TX
Click here to add this to my saved trials
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated:  10/12/2012
Clinical Research Facility
mi
from
Dallas, TX
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease (CKD) Patients Receiving Chronic Hemodialysis
A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis
Status: Enrolling
Updated: 10/12/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program
Status: Enrolling
Updated:  10/25/2012
Maine Nephrology Associates
mi
from
Portland, ME
Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program
Status: Enrolling
Updated: 10/25/2012
Maine Nephrology Associates
mi
from
Portland, ME
Click here to add this to my saved trials
Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy
A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN)
Status: Enrolling
Updated:  11/6/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy
A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN)
Status: Enrolling
Updated: 11/6/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Single Dose Study of the Pharmacokinetics of MK-4618 in Participants With Renal Insufficiency (MK-4618-014 AM1)
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
mi
from
Tampa, FL
A Single Dose Study of the Pharmacokinetics of MK-4618 in Participants With Renal Insufficiency (MK-4618-014 AM1)
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Single Dose Study of the Pharmacokinetics of MK-4618 in Participants With Renal Insufficiency (MK-4618-014 AM1)
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
mi
from
Tampa, FL
A Single Dose Study of the Pharmacokinetics of MK-4618 in Participants With Renal Insufficiency (MK-4618-014 AM1)
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Single Dose Study of the Pharmacokinetics of MK-4618 in Participants With Renal Insufficiency (MK-4618-014 AM1)
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency
Status: Enrolling
Updated:  11/6/2012
Clinical Research Facility
mi
from
Neptune, NJ
A Single Dose Study of the Pharmacokinetics of MK-4618 in Participants With Renal Insufficiency (MK-4618-014 AM1)
An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency
Status: Enrolling
Updated: 11/6/2012
Clinical Research Facility
mi
from
Neptune, NJ
Click here to add this to my saved trials